Forward P/E of 5.91x and forward EV/EBITDA of 3.72x sit materially below their trailing counterparts of 9.56x and 4.41x, which mathematically embeds an earnings rebound; because management withheld guidance at the October 27, 2026 report, that rebound appears to be a market assumption rather than a company-validated one. The 0.59x price-to-sales and 0.55x price-to-book multiples should be read against a balance sheet carrying roughly 28% goodwill, so the apparent asset discount may partly reflect skepticism about carrying value rather than a textbook deep-value signal. The 0.40 PEG screens as cheap against the ~9.0% trailing revenue growth, but with four consecutive quarters of year-over-year decline, that growth input looks stale relative to the current trajectory.

Net margin is the least reliable read of earning power here, swinging from 12.3% in 2024Q3 to -49.0% in 2026Q2 and back to 9.2% in 2026Q4, a range driven by below-the-line charges rather than operating performance; operating margin, adjusted for the acquisition and integration costs flagged in prior analysis, appears to be the more faithful proxy. Notably, FCF margin of 19.5% in 2026Q4 versus a 0.8% reading in 2026Q2 suggests cash generation has held up better than reported profitability, though the 12.4 percentage point swing between adjacent quarters indicates this measure is itself volatile. Investors should treat the sequential gross margin recovery from 30.3% to 34.0% cautiously, as it coincides with revenue contraction and may partly reflect mix or cost relief rather than restored pricing power.

Annualizing the latest readings implies ROIC of roughly 8% and ROE of roughly 8%, both below the approximately 10% implied by the 2024Q3 figures, which suggests the business is compounding capital at a lower rate than two years prior rather than simply experiencing a one-period shock. Because asset turnover has been range-bound between 0.14 and 0.17 across the entire ten-quarter window, the entire decline in returns appears attributable to margin compression, meaning a recovery in gross margin — not better asset productivity — would be the swing factor. One caveat on ROE: the equity base has shrunk from about $1.8B to $1.5B on cumulative losses and buybacks, so a mechanically higher ROE could emerge without any genuine improvement in operating returns, a distinction worth monitoring against ROIC.

Receivables discipline appears intact, with DSO confined to a 35-40 day band across all ten quarters, so the deterioration is concentrated on the inventory and payables legs; DPO has eased to 21 days in 2026Q4 from a 30-day high in 2026Q1, which may indicate suppliers are shortening terms or the company is accelerating payments, though contract details are not disclosed. In an asset-light co-manufacturing model where PP&E is only about $91.5M, inventory becomes the dominant working capital risk, and 61 days on hand against four straight quarters of declining revenue suggests stock is turning over more slowly than the business model assumes. Asset turnover of 0.15-0.17 is structurally low versus peers with owned distribution or retail footprints, so this ratio should not be benchmarked against asset-heavy packaged-food names without adjustment.

Absolute leverage remains modest at $397.6M of debt against roughly $1.5B of equity and $138.4M of cash, positioning SMPL well below leveraged peers such as Nomad Foods at 0.92 and Hain Celestial at 1.64 debt-to-equity, so refinancing or near-term solvency stress does not appear to be the binding constraint. The rising debt/EBITDA multiple and erratic coverage — from 12.17x in 2025Q3 to -36.38x in 2026Q2 — appear driven by EBITDA denominator volatility rather than incremental borrowing, which means covenant headroom should be evaluated against a normalized EBITDA run-rate rather than any single quarter. The current ratio of 5.57 and quick ratio of 3.87 indicate ample short-term capacity, but investors should monitor whether the leverage drift continues as losses compound against a shrinking equity base.